Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The burosumab group had a numerically lower mean phosphate Z-score (−4.07 [−4.60, −3.54] and −3.57 [−4.03, −3.12], respectively) and 1,25(OH)2D (39.79 pg/mL [33.00, 46.58] and 52.75 pg/mL [46.75, 58.74], respectively) than the non-burosumab group.

Source: Demographic characteristics at enrollment and at the SoB treatment. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The SUNFLOWER study is an ongoing prospective cohort study (up to 10 yr) conducted at 17 Japanese and 3 South Korean institutions.

Source: Methods.

Patients were excluded if they were participating in another clinical trial at the time of obtaining consent, or if the principal investigator or sub-investigator judged them as unsuitable for participation.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effectiveness of burosumab in children with X-linked hypophosphatemia with low rickets severity: SUNFLOWER analysis

Cohort study · JBMR Plus · 2026

Original publication title

Effectiveness of burosumab in children with X-linked hypophosphatemia with low rickets severity: SUNFLOWER analysis

Hee Gyung Kang; Toshimi Michigami; Noriyuki Namba; Nobuaki Ito; Takuo Kubota; Osamu Miyazaki; Masanori Kanematsu; Chikako Hayashi; Haruka Ishii; Seiji Fukumoto; Keiichi Ozono

© The Author(s) 2026. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Abstract

Burosumab provides treatment benefits in children with X-linked hypophosphatemia (XLH). However, children with low rickets severity (Rickets Severity Score [RSS] < 2) were excluded from a previous phase 3, multicenter, active comparator-controlled randomized clinical trial. This descriptive interim analysis of the prospective SUNFLOWER (Study of longitUdinal observatioN For patients with X-Linked hypOphosphatemic rickets/osteomalacia in collaboration With Asian partnERs) cohort study included 69 children with XLH aged ≤13 yr at enrollment. The burosumab and non-burosumab groups included 48 and 65 participants, respectively, with some overlap due to switching.

Longitudinal changes in height and biochemical parameters (overall and stratified by disease severity [RSS <2/≥2; alkaline phosphatase </≥ upper limit of normal]) were assessed. In the burosumab all-patients analysis (irrespective of treatment duration or missing follow-up data), height Z-score (initiation: −2.04 ± 1.08; 3 yr: −1.58 ± 1.09), serum phosphate Z-score (initiation: −4.07 ± 1.77; 3 yr: −2.30 ± 1.45), 1,25(OH)2D (initiation: 39.79 ± 22.78 pg/mL; 3 yr: 84.35 ± 28.26 pg/mL), and ratio of tubular maximum phosphate reabsorption to glomerular filtration rate Z-score (initiation: −4.51 ± 2.60; 3 yr: −0.93 ± 2.50) tended to be higher at 3 yr following burosumab treatment.

Rickets Severity Score (initiation: 2.38 ± 1.44; 3 yr: 0.83 ± 0.53) and alkaline phosphatase Z-score (initiation: 3.11 ± 1.79; 3 yr: 1.71 ± 1.14) tended to be lower at 3 yr. The subgroup analyses by RSS also showed similar results. Height Z-score, phosphate Z-score, and 1,25(OH)2D tended to be higher at 3 yr in both subgroups, while alkaline phosphatase Z-score tended to be lower. In the subgroup analysis by alkaline phosphatase status, height Z-score tended to be higher at 3 yr only in the ≥upper limit of normal subgroup; the other results were comparable.

Overall, height, phosphate homeostasis, and bone health may improve in children with XLH (including RSS <2) following burosumab treatment.

Lay Summary X-linked hypophosphatemia (XLH) is a genetic condition characterized by low phosphate and active vitamin D, resulting in bone deformities, rickets, and poor growth in children. Burosumab provides treatment benefits to XLH patients. However, the benefits have mainly been demonstrated in children with more severe disease. We investigated whether burosumab benefits children with mild disease. We showed that burosumab tended to increase height, phosphate, and active vitamin D, and decrease rickets severity, in children with mild disease. Therefore, burosumab may benefit children with mild XLH.

Authors’ abstract

Abstract

Burosumab provides treatment benefits in children with X-linked hypophosphatemia (XLH). However, children with low rickets severity (Rickets Severity Score [RSS] < 2) were excluded from a previous phase 3, multicenter, active comparator-controlled randomized clinical trial. This descriptive interim analysis of the prospective SUNFLOWER (Study of longitUdinal observatioN For patients with X-Linked hypOphosphatemic rickets/osteomalacia in collaboration With Asian partnERs) cohort study included 69 children with XLH aged ≤13 yr at enrollment. The burosumab and non-burosumab groups included 48 and 65 participants, respectively, with some overlap due to switching.

Longitudinal changes in height and biochemical parameters (overall and stratified by disease severity [RSS <2/≥2; alkaline phosphatase </≥ upper limit of normal]) were assessed. In the burosumab all-patients analysis (irrespective of treatment duration or missing follow-up data), height Z-score (initiation: −2.04 ± 1.08; 3 yr: −1.58 ± 1.09), serum phosphate Z-score (initiation: −4.07 ± 1.77; 3 yr: −2.30 ± 1.45), 1,25(OH)2D (initiation: 39.79 ± 22.78 pg/mL; 3 yr: 84.35 ± 28.26 pg/mL), and ratio of tubular maximum phosphate reabsorption to glomerular filtration rate Z-score (initiation: −4.51 ± 2.60; 3 yr: −0.93 ± 2.50) tended to be higher at 3 yr following burosumab treatment.

Rickets Severity Score (initiation: 2.38 ± 1.44; 3 yr: 0.83 ± 0.53) and alkaline phosphatase Z-score (initiation: 3.11 ± 1.79; 3 yr: 1.71 ± 1.14) tended to be lower at 3 yr. The subgroup analyses by RSS also showed similar results. Height Z-score, phosphate Z-score, and 1,25(OH)2D tended to be higher at 3 yr in both subgroups, while alkaline phosphatase Z-score tended to be lower. In the subgroup analysis by alkaline phosphatase status, height Z-score tended to be higher at 3 yr only in the ≥upper limit of normal subgroup; the other results were comparable.

Overall, height, phosphate homeostasis, and bone health may improve in children with XLH (including RSS <2) following burosumab treatment.

Lay Summary X-linked hypophosphatemia (XLH) is a genetic condition characterized by low phosphate and active vitamin D, resulting in bone deformities, rickets, and poor growth in children. Burosumab provides treatment benefits to XLH patients. However, the benefits have mainly been demonstrated in children with more severe disease. We investigated whether burosumab benefits children with mild disease. We showed that burosumab tended to increase height, phosphate, and active vitamin D, and decrease rickets severity, in children with mild disease. Therefore, burosumab may benefit children with mild XLH.

Publication and source details

Original title: Effectiveness of burosumab in children with X-linked hypophosphatemia with low rickets severity: SUNFLOWER analysis

Hee Gyung Kang; Toshimi Michigami; Noriyuki Namba; Nobuaki Ito; Takuo Kubota; Osamu Miyazaki; Masanori Kanematsu; Chikako Hayashi; Haruka Ishii; Seiji Fukumoto; Keiichi Ozono

JBMR Plus · 2026

Corresponding author: Hee Gyung Kang, Department of Pediatric Nephrology, Seoul National University Children’s Hospital, Seoul 03080, Republic of Korea (kanghg@snu.ac.kr).© The Author(s) 2026. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Kyowa Kirin Co., Ltd.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:26:01.485141+00:00

DOI: 10.1093/jbmrpl/ziag168 · PMC13732572